Overview

This trial is active, not recruiting.

Condition brain disease
Treatments gadobenate, gadoterate
Phase phase 4
Sponsor Bracco Diagnostics, Inc
Start date February 2014
End date July 2015
Trial size 176 participants
Trial identifier NCT02070380, MH-148

Summary

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model crossover assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose diagnostic
Arm
(Active Comparator)
MRI with MultiHance 0.05 mmol/kg
gadoterate Dotarem 0.1 mmol/kg
(Active Comparator)
Dotarem 0.1 mmol/kg
gadobenate MultiHance 0.05 mmol/kg or
(Active Comparator)
MultiHance 0.1 mmol/kg
gadoterate Dotarem 0.1 mmol/kg

Primary Outcomes

Measure
Scores on global diagnostic preference
time frame: Up to 14 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Are at least 18 years of age or older - Are able to give written informed consent and are willing to comply with the protocol requirements - Are scheduled to undergo MRI - Are willing to undergo two MRI procedures within 14 days - Have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by: - Clinical/neurological symptomatology; - Diagnostic testing, such as CT or previous MRI examinations; or - Have had recent brain surgery and are to be evaluated for recurrence Exclusion Criteria: - Are pregnant or lactating females. Exclude the possibility of pregnancy: - By testing on site at the institution within 24 hours prior to the start of each investigational product administration; or - By history (i.e., tubal ligation or hysterectomy); or - Post menopausal with a minimum of 1 year without menses - Have any known allergy to one or more of the ingredients in the investigational products, or have a history of hypersensitivity to any metals - Have congestive heart failure (class IV according to the classification of the New York Heart Association) - Have suffered a stroke within a year - Have received or are scheduled to receive any other contrast medium in the 24 hours preceding through the 24 hours following Exam 1, and in the 24 hours preceding through the 24 hours following Exam 2 - Have received or are scheduled to receive an investigational compound and/or medical device within 30 days before admission into the present study, through the 24 hours post-administration of the second investigational product - Have moderate-to-severe renal impairment, defined as Glomerular Filtration Rate (GFR)/estimated GFR < 45 mL/min - Have been previously entered into this study - Have received or are scheduled for one of the following: - Surgical or chemotherapeutic treatment within three weeks prior to the first examination or between the two examinations - Initiation of steroid therapy between the two examinations - Radiosurgery between the two examinations - Have any contraindications to MRI such as a pace-maker, magnetic material (i.e., surgical clips) or any other conditions that would preclude proximity to a strong magnetic field - Are suffering from severe claustrophobia - Have any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations

Additional Information

Official title Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in Magnetic Resonance Imaging (MRI) of the Brain
Trial information was received from ClinicalTrials.gov and was last updated in February 2015.
Information provided to ClinicalTrials.gov by Bracco Diagnostics, Inc.